Clinical Tolerability and Quality of Life Assessment of a Novel Panthenol and Bisabolol-enhanced Cream and Lotion in Adults with Mild to Moderate Dermatologic Conditions

Background: Adults with common dermatologic conditions such as acne, rosacea, eczema, and psoriasis, and those with irritated, sensitive, or reactive skin, often have altered skin barrier function and/or heightened susceptibility to irritation from topical products. Moisturizers used daily by these populations must demonstrate tolerability on clinically characterized sensitive skin. Objectives: We describe here the clinical evaluation of investigator-assessed and subject-assessed tolerability of a novel panthenol plus bisabolol-enhanced cream and lotion, and their impact on clinical skin condition and dermatology-related quality of life across a diverse range of dermatologic diseases and skin phototypes, after 4 weeks of twice-daily use. Materials and Methods: A single-center, subject-masked study in adults (N=315; n=160, cream; n=155, lotion) aged 18 years and older with Fitzpatrick skin types I to VI and mild to moderate acne-prone skin, rosacea, eczema-prone skin (not currently flaring), psoriasis, or irritated, sensitive, and reactive skin was conducted. Subjects were assigned to one product, applied twice daily to the entire body (face optional) in place of their current moisturizer for 4 weeks. Investigator-graded signs (dryness, erythema, desquamation, irritation) and subject-reported symptoms (dryness, tightness, stinging, itching, burning) were scored on 5-point ordinal scales (0=none to 4=severe) at baseline and Weeks 1, 2, and 4, with a disease-related Investigator Global Assessment (IGA) of overall clinical skin condition (0=clear to 4=severe skin issues). The Dermatology Life Quality Index (DLQI) was completed at baseline and Week 4. Adverse events were monitored throughout the study. Results: Investigator-graded signs were minimal at baseline and remained low or improved through Week 4 with both products. Subject-reported symptoms improved significantly from baseline (p≤0.05): mean dryness decreased from 2.87 to 0.34 with the cream and from 2.59 to 0.29 with the lotion, with parallel reductions in tightness, stinging, itching, and burning. Mean IGA scores improved significantly by Week 1, with continued improvement through Week 4 (cream, 2.1 to 0.71; lotion, 2.16 to 0.75; p≤0.05). Mean DLQI decreased by approximately 85% from baseline to Week 4 in both groups (cream, 4.96 to 0.68; lotion, 3.92 to 0.62; p≤0.05). No adverse events were reported during the study. Conclusions: Both novel formulations (cream and lotion) which include hyaluronic acid, ceramides, glycerin, and vitamin E enhanced with panthenol and bisabolol, demonstrated excellent tolerability by investigator and subject assessment and were associated with significant improvements in subject-reported symptoms, investigator-assessed disease related skin condition, and dermatology-related quality of life across a broad range of dermatologic conditions and Fitzpatrick skin types, supporting twice-daily use as part of routine skin care in patients with clinically characterized sensitive skin. Scientific Poster support provided by Beiersdorf, Inc.